



IN SILICO AND IN VITRO ASSAY OF HGV ANALOGUE AS ANTIBACTERIAL 
Original Article 
 
BAMBANG WIJIANTOab, RITMALENIa*, HARI PURNOMOa, ARIEF NURROCHMADa 
a
Received: 31 Oct 2018 Revised and Accepted: 26 Jan 2019 
Faculty of Pharmacy, Universitas Gadjah Mada Yogyakarta 55281 and University of Tanjungpura, Pontianak, Indonesia 
Email: ritmaleni@ugm.ac.id 
ABSTRACT 
Objective: The objective of this research was to design a new analogue compound, hexagamavunon (HGV). 
Methods: New design of analogue compound, HGV, was performed by QSAR study using BuildQSAR program. In this QSAR study, parameterized 
model (PM3) method using the Polak-Ribière algorithm was applied to calculate the optimal geometric structures of the used compounds. The new 
analogue compound, HGV had been synthesized using aldol condensation reaction. The assay of antibacterial activities was performed using the 
dilution method. Molecular operating environment (MOE) program was used for protocol docking.  
Results: The results of QSAR study reveal the good relationship of antibacterial activities. The in vitro antibacterial activities of 2,6-bis((E)-3,5-
dibromo-4-hydroxybenzylidene) cyclohexan-1-one (A113) indicates the good potential to against S. aureus, B. subtilis and E. coli with IC50
Conclusion: Based on in silico and in vitro assay, 2,6-bis((E)-3,5-dibromo-4-hydroxybenzylidene) cyclohexan-1-one (A113) has good antibacterial 
activities against S. aureus, B. subtilis, and E. coli. 
 27.3 
μg/ml, 30.9 μg/ml, 32 μg/ml respectively. This is in accordance with the in silico evaluation showing that 2,6-bis((E)-3,5-dibromo-4-
hydroxybenzylidene) cyclohexan-1-one has lower docking score than both amoxicillin and cefoxitin do as the native ligand of receptor 3MZE. 
Keywords: In silico, In vitro, 2,6-bis((E)-3,5-dibromo-4-hydroxybenzylidene)cyclohexan-1-one, Antibacterial 




Heksagamavunon (HGV), pentagamavunon (PGV) and gamavuton 
(GVT) are mono-ketone analogue compounds which have been 
successfully synthesized and patented. Basically, they are curcumin 
analogues [1] that have biological activities including anti-
inflammatory, antioxidant, and antibacterial [1, 2]. The basic 
differences of the three compounds refer to the carbonyl ketone group 
that connects two rings of benzene aromatic (fig. 1). The analogue 
compounds were synthesized using aldol condensation [1, 3]. 
Bacteria are dangerous microorganisms, some bacteria cause health 
problems such as typhoid [4], common cold [5], syphilis [6], and 
more. S. aureus, B. subtilis and E. coli are Gram-positive and Gram-
negative bacteria respectively that commonly lead to some diseases 
such as pneumonia, meningitis, and diarrhea [7]. In addition, they 
are organism model that is frequently used in antibiotic screening 
studies [8]. The bacteria are less pathogenic so that they are saved 
for laboratory experiments. 
The drug design for finding new types of medicine can be done using 
computational chemistry method. This was applied to redesign the 
molecules of lead compounds for better biological activities and less 
side effects. Considering time and cost efficiency, quantitative 
structure-activity relationship (QSAR) is a computational method 
which can be mainly implemented in finding new drugs. Moreover, it 
is possible to implement to avoid trial and error with considerable 
significance or credibility level [9]. QSAR study revealed the 
quantitative relationship of microscopic (molecular structure) and 
macroscopic (biological activity) of a molecule. The study on 
analogue compounds, HGV, PGV, and GVT, was performed for 
antioxidant activities [10]; it is possible to conduct to predict 
antibacterial activities.  
The objective of this research was to design new analogue 
compounds involving HGV, PGV, and GVT that are potential to be 
used as antibacterial. They were synthesized and evaluated for their 
antibacterial activities against S. aureus, B. subtilis and E. coli using 




Fig. 1: Basic framework of HGV, PGV, and GVT analogues 
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The drug design for finding new types of medicine can be done using 
computational chemistry method. This was applied to redesign the 
molecules of lead compounds for better biological activities and less side 
effects. Considering time and cost efficiency, quantitative structure-
activity relationship (QSAR) is a computational method which can be 
mainly implemented in finding new drugs. Moreover, it is possible to 
implement to avoid trial and error with considerable significance or 
credibility level [9]. QSAR study revealed the quantitative relationship of 
microscopic (molecular structure) and macroscopic (biological activity) 
of a molecule. The study on analogue compounds, HGV, PGV, and GVT, 
was performed for antioxidant activities [10]; it is possible to conduct to 
predict antibacterial activities.  
The objective of this research was to design new analogue 
compounds involving HGV, PGV, and GVT that are potential to be 
used as antibacterial. They were synthesized and evaluated for their 
antibacterial activities against S. aureus, B. subtilis and E. coli using 
the liquid dilution method [11, 12].  
MATERIALS AND METHODS 
Data set QSAR 
In QSAR study, the data set used involve nine compounds of HGV, 
PGV and GVT analogue (unpublished Ritmaleni’s collection) with 
their antibacterial activities against S. aureus, ten compounds of 
HGV, PGV and GVT analogue (unpublished Ritmaleni’s collection) 
with their antibacterial activities against B. subtilis, and nine 
analogue compounds of HGV, PGV and GVT analogue (unpublished 
Ritmaleni’s collection) with their antibacterial activities against E. 
coli (table 1). The in vitro antibacterial activities were interpreted as 




Table 1: HGV, PGV, GVT analogues used as data set for QSAR 
Comp. Substitute S. aureus Log IC50 B. subtilis Log IC50 E. coli log IC50 
R1 R2 R3 R4 R5 
A103 H OC2H5 OH H H 1.43 - 2.22 
C113 H Br OH Br H - 2.07 - 
B113 H Br OH Br H - 1.92 1.71 
A114 H Br OH H H 1.91 - - 
A101 H OCH3 OCH3 OCH3 H 3.02 2.71 - 
B101 H OCH3 OCH3 OCH3 H 2.66 2.65 - 
C101 H OCH3 OCH3 OCH3 H 2.66 2.7 2.79 
B115 H Br H H OCH3 2.83 2.74 - 
C115 H Br H H OCH3 - - - 
A145 H H H H OC2H5 - - 2.55 
B145 H H H H OC2H5 2.78 2.66 2.6 
C145 H H H H OC2H5 - - - 
A150 Cl H H H Cl 3.05 - 2.6 
B150 Cl H H H Cl - - 2.71 
C150 Cl H H H Cl 2.39 2.65 - 
A143 Cl H H H F - 2.41 2.37 
C143 Cl H H H F - 2.26 2.23 
 
Instrumentation  
In the QSAR study, a PC with the processor of Intel Core i3-6006U 2.0 
GHz, 4GB, Windows 7 Operating System was used. All calculations of 
quantum mechanics, atomic descriptors and molecular descriptors 
applied HyperChem 7.5 program. The QSAR model was generated using 
MLR analysis with BuildQSAR program. Protocol docking was performed 
with molecular operating environment (MOE) version 2018.0101. 
BUCHI Melting Point B-540 with temperature gradient at 5 °C/min 
was used for melting point test. The purity of compounds was 
measured using GC17A MSQP 5000 Shimadzu. JEOL 500 MHz 
spectrophotometer was used to measure 13
Procedure 
C NMR Spectrum. All of 
the starting materials were obtained from Sigma Aldrich. The 
solvent materials used are Synthesis grade and Pro analysis. 
QSAR study 
Geometric optimization 
Each leading compound used in the QSAR study (table 1) was 
transformed into a two-dimensional structure (2D) (fig. 1) with 
HyperChem program. Atom H was added to complete the structure 
to transform it into the three-dimensional structure (3D). Its 
geometric structure was then optimized with PM3 semi-empirical 
method using the Polak-Ribière algorithm [10]. 
Descriptor calculation 
The single point calculation was conducted for the optimized three-
dimensional structures using HyperChem program. This was to 
obtain the electronic parameters such as atom C’s net charge, total 
energy (E total), binding energy (BE) and heat of formation (HF); 
lipophilicity parameters; and steric parameters (molecule size) of 
each molecule using the HyperChem program [10].  
Statistical analysis 
All of the descriptors were analyzed with multilinear regression (MLR) 
in order to find the antibacterial activities using BuildQSAR program. The 
best equation models resulted were selected, considering its best 
statistical parameters, and were used to predict its antibacterial 
activities. The best statistical parameters involve the highest R 
(regression), the largest F ratio, the smallest s value, the smallest PRESS 
statistic (the predicted residual sum of squares), and the lowest Q2. The 
selected equations were validated using the available leave-one-out 
cross-validation (LOOCV) method of BuildQSAR program.  
Docking studies 
Preparation of ligand structures 
A113 (2,6-bis((E)-3,5-dibromo-4-hydroxybenzylidene) cyclohexan-
1-one) and cefoxitin, the reference molecules of the docking 
simulations, were built in the two-dimensional model in the form of 
MOE database. The determination of conformation was then 
performed on the database using import conformation. 
Furthermore, its minimal energy was calculated. 
Docking simulations 
The 3D Penicillin-Binding Protein 5 (PBP5) was obtained from Protein 
Data Bank (https://www. rcsb. org/; PDB ID code: 3MZE) [13]. Protein 
contains a reference molecule that is cefoxitin (3a) as the native ligand. 
The protein binding sites were managed using modules of Ligand Atoms 
Selection of MOE, and the cefoxitin binding sites were used in crystal 
structure as a reference. The sequence order of the binding sites was set 
using MOE program. Hydrogen was added to complete the protein 
structure using selected Protonate 3D of MOE program; only ligand and 
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protein chain A of the crystal structure was used. The protein was then 
aligned using Align module of MOE. For the docking simulation process, 
the placement was managed on triangular matcher, rescoring was 
managed on London dG parameter, and the conformation number was 
managed in 10 poses; conformation was selected as the forcefield of 
MOE and was used to generate 10 poses. As the results of docking run, 
the output file is in mdb form with the scoring of some conformations. All 
of the docking conformations were analyzed, and the best value with the 
precise pose was selected for the further interactional study.  
General procedure for synthesis of A113 (2,6-bis((E)-3,5-
dibromo-4-hydroxybenzylidene) cyclohexan-1-one)  
3.572 mol 3,5,-dibromo-4-dihydroxybenzaldehyde, 1.786 mol 
cyclohexanone, 2.0 ml THF and 0.2 ml of concentrated hydrochloric 
acid were stirred for two hours at 50 °C, and the stirring was 
continued for 8 h at room temperature. After set aside for 3 d, the 
mixture was treated with cold ethanol-water (1:1), filtered and the 
residue was dried. TLC, melting point, was used to confirm the 
purity of the compound. 
2,6-bis((E)-3,5-dibromo-4-hydroxybenzylidene) cyclohexan-1-
one (A113) 
Reddish yellow powder, yield 34.84 %, mp>300 °C; IR γ (cm-1) 
(KBr): 3485.75–OH stretch non bonded, 2928.87 =C-H stretch 
aromatic, 1597.95 C=O stretch α β, α’ β’-unsat, 1475.35 C=C stretch 
aromatic, 1165.12 C-O stretch. 13C-NMR (500 MHz, Asetone-d6) δ 
(ppm): 206.258 (C=O ketone), 188.875 (C-OH), 151.987 (C-C 
aromatic, ketone), 137.550 (C=C aliphatic), 133.941 (C-Br). 1
 
HNMR 
(300 MHz, Asetone-d6) δ: 8.98 (s, 1H, OH), 7.73 (s, 1H, Ar-H), 7.531 
(s, 1H, aliphatic), 2.97-2.94 (4H, ketone-H), 2.05-2.04 (2H, ketone-H). 
 
Scheme 1: Reagent and conditions of synthesis: (a) THF and HCl; 8 h 
 
In vitro antibacterial activity assay 
The antibacterial activities against ATCC 6538P, B. subtilis ATCC 
6633 and E. coli ATCC 25922 were tested using liquid dilution 
method. For in vitro assay, A113 was prepared. BHI media (50 µl) 
was added into microplate 96 well; experimental compound (50 µl) 
was added into 1A until 1E column. The obtained concentrations of 
the dilution method is 0.5 mg/ml, 0.25 mg/ml, 0.125 mg/ml, 0.063 
mg/ml, and 0.031 mg/ml respectively. Selected bacteria (50 µl) was 
added into each well. Solvent control, compound control, and media 
control were prepared in the same microplate. The incubation was 
conducted for 24 h at 37 °C. It was then measured using microplate 
reader (595 nm). This method was used to determine the inhibitory 
concentration of the investigated compounds which showed 
inhibitory effect on the growth of the tested bacteria. This 
concentration was considered as inhibitory concentration (IC50
The new compound design of HGV, PGV, and GVT analogues as 
antibacterial was conducted based on QSAR study using BuildQSAR. 
The best equation of QSAR was selected for predicting the 
antibacterial activities against S. aureus, B. subtilis and E. coli. The 
selection of descriptors was conducted using systematic search (SS) 
method. QSAR model consists of one to five variables; it must have 
correlation criteria, r>0.8 and forbid cross-correlation (Rij)>0.6. 
BuildQSAR was validated using leave-one-out cross-validation.  
). 
RESULTS AND DISCUSSION 
Selection of the best model 
X1 and X5 were found on the selected variables; it shows the number 
of selected variables. In addition, the values of R, s, F, Q2, SPress, SDep 
were identified. The selection was based on the best statistical 
parameters including the highest R (regression), the largest F ratio, the 
smallest s value, the smallest PRESS statistic (the predicted residual 
sum of squares), and the lowest Q2. The calculation of MLR of the 
descriptors of S. aureus, B. subtilis and E. coli using BuildQSAR provides 
4 QSAR models as shown in table 2, table 3, and table 4.  
Basically, the best model selected was based on the number of 
variables and statistical parameters of the model [14]. The results 
indicate that all models reveal the linear correlation of biological 
activities and descriptors as indicated by the R-value of each model.  
The QSAR equation model (1) of each table was selected for 
predicting the antibacterial activities (log IC50
 
) against S. aureus 
(table 2), B. subtilis (table 3), and E. coli (table 4); it is the best QSAR 
model. The equation (1) of each table was selected as it has the most 
number of variable, the highest R (regression), the largest F (Fisher) 
coefficient, and the smallest PRESS statistic (the predicted residual 
sum of squares). Considering the smallest value, the equation was 
considered as a model closed to the experimental results. 
Table 2: Statistical model QSAR and parameter statistical of MLR result against S. aureus 
No. Descriptor n m R s F p Q2 SPress SDep 
1. qC11, qC15, qC16, 
qC17, Volum 
9 5 0.998 0.052 171.136 0.0007 0.951 0.194 0.119 
 Equation Log IC50
2. 
 =-7.5725(±2.9753) qC11-6.0978(±0.7519) qC15-7.9387(±1.3551) qC16-8.3101(±1.7492) 
qC17+0.0061(±0.0010) Volum-5.5336(±1.3713)  
qC4, qC5, qC14, Mass 9 4 0.986 0.125 36.048 0.0021 0.864 0.281 0.198 
 Equation Log IC50
3. 
 =+17.9885(±4.6196) qC4+5.5044(±2.0227) qC5+4.9255(±1.6793) qC14+0.0057(±0.0035) 
Mass+3.5267(±1.3433)  
qC4, Mass, Surface 
Area (SA) 
9 3 0.979 0.138 38.698 0.0007 0.867 0.248 0.196 
 Equation Log IC50
4. 
 =+18.1619(±4.7645) qC4+0.0080(±0.0035) Mass+0.0064(±0.0020) SA-1.9560(±1.6218)  
qC1, E Hydration 9 2 0.931 0.227 19.506 0.0024 0.685 0.348 0.301 
 Equation Log IC50  =+4.0200(±2.6086) qC1+0.1221(±0.0491) E Hydra+3.3811(±0.3852)  
n = number of data, m = number of variable, R= correlation coefficient, s = standard error, F = Fisher coefficient, SPress = Predictive Error Sum of 
Squares.  
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The best equation model generated from QSAR study of S. aureus is 
Log IC50 =-7.5725 (±2.9753) qC11-6.0978 (±0.7519) qC15-7.9387 
(±1.3551) qC16-8.3101 (±1.7492) qC17+0.0061 (±0.0010) Volume-
5.5336 (±1.3713). The equation was used to design new HGV, PGV 
and GVT analog with antibacterial activities against S. aureus. Based 
on the model, the five variables (qC11, qC15, qC16, qC17, Volume) 
have significant effects on IC50 
  
value. The model has R correlation 
(0.988), Fisher coefficient (171.1336), s value (0.052) and PRESS 
statistic (0.194), showing that the model is closed to the 
experimental results. 
Table 3: Statistical model QSAR and parameter statistical of MLR result against B. subtilis 
No. Descriptor n m R s F p Q2 SPress SDep 
1. qC3, qC7, qC14, E Homo, E 
Lumo 
10 5 0.999 0.022 314.092 <0.0001 0.985 0.054 0.036 
 Equation Log IC50
2. 
 =-2.1710(±0.2592) qC3-10.9207(±3.0630) qC7+1.9909(±0.3572) qC14+1.1712(±0.2004) E Homo-
0.1840(±0.1227) E Lumo+13.1381(±1.6947)  
qC3, qC7, qC14, E Homo 10 4 0.993 0.046 91.018 0.0001 0.946 0.093 0.069 
 Equation Log IC50
3. 
 =-2.2830(±0.4747) qC3-7.3596(±3.7010) qC7+2.3556(±0.5006) qC14+0.9164(±0.2034) E 
Homo+11.0401(±1.8293)  
qC14, EHomo, EHydration 10 3 0.973 0.084 35.699 0.0003 0.872 0.130 0.106 
 Equation Log IC50
4. 
 =+2.2158(±0.8318) qC14+0.7866(±0.3162) E Homo+0.0650(±0.0194) E hydr+10.2998(±2.9280)  
qC2, qC3 10 2 0.881 0.159 12.138 0.0053 0.625 0.206 0.182 
 Equation Log IC50 =+3.4866(±1.8956) qC2-1.7717(±1.3208) qC3+2.8625(±0.2275)  
n = number of data, m = number of variable, R= correlation coefficient, s = standard error, F = Fisher coefficient, SPress = Predictive Error Sum of Squares
 
Table 4: Statistical model QSAR and parameter statistical of MLR result against E. coli 
No. Descriptor n m R s F p Q2 SPress SDep 
1. qC2, qC11, qC12, E 
Hydration, Mass 
9 5 1.000 0.008 2954.907 <0.0001 0.981 0.074 0.045 
 Equation Log IC50
2. 
 =+7.5805(±0.4244) qC2+6.7449(±0.5069) qC11+1.6726(±0.5181) qC12+0.1204(±0.0067) E 
hydr+0.0031(±0.0003) Mass+2.7435(±0.0978)  
qC2, qC13, E Hydration, 
Surface Area (SA) 
10 4 0.993 0.046 91.018 0.0001 0.946 0.093 0.069 
 Equation Log IC50
3. 
 =+3.8354(±0.4729) qC2-0.6987(±0.2637) qC13+0.0850(±0.0064) E hydr+0.0021(±0.0004) 
SA+1.9206(±0.2315)  
qC4, qC16, Surface Area (SA) 9 3 0.994 0.047 132.012 <0.0001 0.944 0.100 0.079 
 Equation Log IC50
4. 
 =+8.6541 (±1.3551) qC4+2.8786 (±0.5855) qC16+0.0016 (±0.0008) SA+2.9920 (±0.4357)  
qC4, qC16 9 2 0.955 0.114 30.878 0.0007 0.708 0.208 0.180 
 Equation Log IC50  =+7.2988(±2.7772) qC4+3.3001(±1.2774) qC16+3.8190(±0.4727)  
n = number of data, m = number of variable, R= correlation coefficient, s = standard error, F = Fisher coefficient, SPress = Predictive Error Sum of Squares  
 
Table 5: The comparison between calculated and experimental antibacterial activity (log IC50
No. 
) against S. a ureus, B. subtilis and E. coli by 
BuildQSAR 
Bacteria Comp Log IC50 Log IC experimental 50 calculation 
1. S. aureus A103 1.43 1.47 
  A114 1.91 1.88 
  A101 3.02 3.08 
  B101 2.66 2.64 
  C101 2.66 2.68 
  B115 2.83 2.82 
  B145 2.78 2.80 
  A150 3.05 3.05 
  C150 2.39 2.44 
2. B. subtilis A143 2.41 2.41 
  C143 2.26 2.27 
  A113 2.07 2.09 
  B113 1.92 1.90 
  A101 2.71 2.72 
  B101 2.65 2.65 
  C101 2.70 2.70 
  B115 2.74 2.72 
  B145 2.66 2.67 
  C150 2.65 2.65 
3. E. coli A143 2.37 2.38 
  C143 2.23 2.25 
  B113 1.71 1.74 
  A103 2.22 2.24 
  A145 2.55 2.57 
  A150 2.60 2.62 
  C101 2.79 2.80 
  B145 2.60 2.62 
  B150 2.71 2.74 
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The best equation model generated from QSAR study of B. subtilis is Log 
IC50 =-2.1710 (±0.2592) qC3-10.9207 (±3.0630) qC7+1.9909 (±0.3572) 
qC14+1.1712 (±0.2004) E Homo-0.1840 (±0.1227) E Lumo+13.1381 
(±1.6947). The equation was used to design new HGV, PGV and GVT 
analog with antibacterial activities against B. subtilis. Based on the model, 
the five variables (qC3, qC7, qC14, EHomo, ELumo) have significant 
effects on IC50 
The best equation model generated from QSAR study of E. coli is Log 
IC
value. The model has R correlation (0.999), Fisher 
coefficient (314.092), s value (0.022) and PRESS statistic (0.054), 
showing that the model is closed to the experimental results. 
50 =+7.5805 (±0.4244) qC2+6.7449 (±0.5069) qC11+1.6726 
(±0.5181) qC12+0.1204 (±0.0067) E hydr+0.0031 (±0.0003) 
Mass+2.7435 (±0.0978). The equation was used to design new HGV, 
PGV and GVT analog with antibacterial activities against E. coli. 
Based on the model, the five variables (qC2, qC11, qC12, E 
Hydration, Mass) have significant effects on IC50 
The prediction of antibacterial activities against S. aureus, B. subtilis, 
and E. coli of 9 to 10 test set which was resulted from the best 
equation was compared and plotted with experimental data using 
linear regression calculation to identify the correlation of each 
equation as shown in table 5 and fig. 2. 
value. The model 
has R correlation (1,000), Fisher coefficient (2954.907), s value 
(0.008) and PRESS statistic (0.074), showing that the model is closed 








Fig. 2: The correlation analysis of result MLR statistical between calculation (Log IC50) and experimental (Log IC50) (a) S. aureus, (b) B. 
subtilis, (c) E. Coli 
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The best QSAR equation model was used as the guideline of 
predicting the antibacterial activities against S. aureus, B. subtilis and 
E. coli in designing the ratio of HGV, PGV, and GVT analog. The 
substituents of R1 to R5 were substituted into a new molecule as the 
descriptor that will influence the antibacterial activities.  
Based on the equation 1 in table 2, to generate the best antibacterial 
activities against S. aureus the charge of atom C11, C15, C16 and C17 
must be positive for small Log IC50. The positive charge of atom C15, 
C16 and C17 can be generated by adding electronegative 
substituents such as hydroxyl and halogen. To influence the positive 
charge of atom C11, either hydroxyl or halogen was added to the 
nearest or neighbouring atom C. 
Based on the equation 1 in table 3, to generate the best antibacterial 
activities against B. subtilis the charge of atom C3, C7, and C14 must 
be positive for small Log IC50. 
Based on the equation 1 in table 4, to generate the best antibacterial 
activities against E. coli. The charge of atom C2, C11 and C12 must be 
negative for small Log IC
The positive charge of atom C3 and 
C14 can be generated by adding electronegative substituents such as 
hydroxyl and halogen. To influence the positive charge of atom C7, 




The negative charge of atom C2 can be 
generated by adding electronegative substituents such as–OH and-
OR. To influence the negative charge of atom C11 and C12, either 
hydroxyl or halogen was added to atom C13 and C17 due to its 
resonance effect that can make the charge of atom C9 and C14 more 
negative. The numbering structure of atom C in the basic structure is 
shown in fig. 3. 
 
Fig. 3: The numbering structure of the C atom in HGV, PGV, GVT 
analogues basic structure 
 
New analogue of HGV, PGV, and GVT with better antibacterial 
activities against S. aureus, B. subtilis, and E. coli is revealed from the 
value of IC50 
 
as shown in table 6, table 7, and table 8. A113 was 
selected for synthesis as its compound design has the potential of 
antibacterial activities against S. aureus, B. subtilis and E. coli. 
Table 6: Design new HGV, PGV and GVT analogues and its predicted antibacterial activity against S. aureus calculated using the best QSAR model 
No. Comp Substitute Log IC50  predict 
R1 R2 R3 R4 R5 
1 A113 H Br OH Br H 1.84 
2 C113 H Br OH Br H 1.72 
 
Table 7: Design new HGV, PGV and GVT analogues and its predicted antibacterial activity against B. subtilis calculated using the best QSAR model 
No. Comp Substitute Log IC50  predict 
R1 R2 R3 R4 R5 
5 A113 H Br OH Br H 1.79 
 
Table 8: Design new HGV, PGV and GVT analogues and its predicted antibacterial activity against E. coli calculated using the best QSAR model 
No. Comp Substitute Log IC50  predict 
R1 R2 R3 R4 R5 
1 A113 H Br OH Br H 1.89 
2 C113 H Br OH Br H 1.54 
 
Docking studies of 2,6-bis((E)-3,5-dibromo-4-hydroxy-
benzylidene) cyclohexan-1-one (A113) 
In this research, in silico evaluation was performed for A113 as an 
antibacterial. A113 was docked into the β-lactam receptor, according 
to the formation stages of peptidoglycan, the basic component of D-
Alanil-D-Alanine formation. The transport enzyme of D-Alanil-D-
Alanin is D-Alanil-D-Alanine decarboxylase (DACA). The enzyme is 
provided by protein data bank with PDB ID code: 3MZE. Protein 
contains a reference molecule that is cefoxitin as native ligand [13]. 
 
 
Fig. 4: Alignment of native ligand (purple) and docked ligand 
(yellow) 
The validation of molecular docking protocol was performed to 
ensure that the receptors are proper to use in the molecular docking 
process. Based on the validation process, the obtained root mean 
square deviation (RMSD) is 1.7753 Å. It is less than 2 Å indicating 
that the docking protocol with receptor PDB 3MZE is valid and 
feasible for the advanced docking process (fig. 4) [15].  
Based on the docking results, conformations and the best favorable 
docking poses with the maximum number of interactions were 
analyzed; they were considered as negative s by MOE software. 
Furthermore, the best docking pose of 10 conformations of each 
compound was analyzed for further investigation of any interactions 
resulted in using active residual sites. The lowest binding energy (s) 
with the most interaction number is compounded with high 
potential of antibacterial agents [17]. The docking results reveal 
proper binding poses with a strong interaction of active residual 
sites of the protein. The 2D-protein ligand interaction was visualized 
using MOE and shown in table 9. 
The docking result of A113 and amoxicillin using receptor PDB ID 
3MZE showed docking score (s) of 13.2599. It is much lower than 
the docking score of cefoxitin, a native ligand, (-10.8382) and 
amoxicillin (-11.5230). The docking score of amoxicillin is higher 
than of A113 and lower than of cefoxitin as the antive ligand. This 
means that A113 is more active as antibacterial than amoxicillin. 
Therefore, A113 was considered as the potential antibacterial 
Ritmaleni et al. 
Int J Pharm Pharm Sci, Vol 11, Issue 3, 78-85 
 
84 
compound. The lower docking score with proper pose results in 
better stability levels of ligand and receptor [16]. The lower binding 
energy (s), the bigger possibility to accept the experimental 
compounds as medicine [17-20]. 
 
Table 9: Docking results with protein PDB ID 3MZE 
Compound S Rmsd_refine E_conf E_place E_score1 E_refine No. of Conf 
A113 -13.2599 3.31144 23.9537 -42.0713 -10.8615 -35.9689 10 
Amoxicillin -11.5230 0.8853 53.8637 -67.6785 -11.1618 -32.3243 10 
Cefoxitin -10.8382 2.6991 65.8911 -74.7419 -11.2002 -40.5919 10 
S-The final score, rmsd_refine-The root mean square deviation between the pose before refinement and the pose after refinement, E_conf-The 
energy of the conformer. E_place-Score from the placement stage, E_score1-Score from the rescoring stage(s), E_refine-Score from the refinement 
stage and No. of conf-number of conformations generated by ligand. 
 
The best docking pose and ligand interaction were selected from each 
compound of A113, amoxicillin, and cefoxitin; they formed a cluster in 




Fig. 5: Binding surface and ligand interaction of compound 




Fig. 6: Binding surface and ligand interaction of compound 
amoxicillin with 3MZE 
 
 
Fig. 7: Binding surface and ligand interaction of compound 
cefoxitin with 3MZE 
 
The docking results reveal that O substituent (C=O, O-H) of A113 
compound has interaction with Asn A112, Asn B112 (same as 
amoxicillin) and Asp A11, Asp B11 residue through sidechain acceptor 
and sidechain donor. Besides that, the aromatic ring of compound 
A113 has an interaction with Leu A153, B153 residue through the 
arene-H bond. In amoxicillin, atom O of the β-lactam ring has 
interaction on Asn A112 and B112 residue through sidechain acceptor; 
whereas, the S group of an aromatic ring has interaction with Ser B44, 
Ser A110, and B110 residue through sidechain acceptor. In cefoxitin, 
atom O (C=O) has interaction with His A216, B126 and Ser A44, B44 
residue through backbone acceptor. Atom S has an interaction with 
Ser A86, B86, A87, B87 residue through backbone acceptor (fig. 5, 6, 
and 7). The confirmation energy of A113 compound, amoxicillin and 
cefoxitin is 23.9537, 53.8637, and 65.8911 respectively, indicating the 
active compounds of the confirmation energy.  
In vitro evaluation of 2,6-bis((E)-3,5-dibromo-4-hydroxy-
benzylidene) cyclohexan-1-one (A113)  
The in vitro evaluation of antibacterial activities was performed 
using dilution method on some bacteria species represented by 
Gram-positive and Gram-negative bacteria. Table 10 and fig. 8 show 
good inhibitory activities 2,6-bis((E)-3,5-dibromo-4-hydroxy-
benzylidene) cyclohexan-1-one (A113) against S. aureus, B. subtilis 
and E. coli. The Inhibitory Concentration 50 (IC 50
Atom Br and OH of A113 is essential for its antibacterial activities. It 
is shown by the conducted docking study. However, some previous 
studies reveal that OH group has also essential roles to inhibit the 
bacterial activities. 
) A113 againts S. 
aureus, B. subtilis, and E. coli is 27.3 μg/ml, 30.9 μg/ml, 32 μg/ml 
respectively. A113 is a potential compound for advanced study.  
Ritmaleni et al. 





 value of A113 against S. aureus, B. subtilis and E. coli 
IC50 (µg/ml) 
S. aureus 27.3 
B. subtilis 30.9 
E. coli 32 
 
   
A B C 
Fig. 8: The result dilution test of A113 against S. aureus (A), E. coli (B), B. subtilis (C) 
 
CONCLUSION  
The results of the research reveal that compound 2,6-bis((E)-3,5-
dibromo-4-hydroxybenzylidene)cyclohexan-1-one (A113), the result 
of QSAR study using BuildQSAR, is a new design of GVT analog proven 
to have antibacterial activities against S. aureus, B. subtilis dan E. coli. 
A113 is potential to be used as drug with antibacterial activities 
through interaction and PBP5 inhibition confirmed by docking studies.  
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